US FDA announces increase in PDUFA fee rates for FY 2011
This article was originally published in SRA
The US Food and Drug Administration has announced the fees it will charge for reviewing prescription drug submissions in fiscal year 2011, reflecting an overall increase compared with the previous year1. The fee for assessing an application requiring clinical data, for example, has been increased by around 9.7% – just over $1.5 million in FY 2011 as compared with approximately $1.4 million in FY 2010.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.